Vir Biotechnology 거래 VIR

매도
 매수

VirBiotechnology 실시간 차트

5m 15m 30m 1h 4h 1d 1w

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

최신 뉴스

Frances Wang 2025 Apr 08, 16:00

GME Stock Price: what’s the risks and challenges ahead of GME stock?

Stocks
Tommy Yap 2025 Apr 08, 16:00

Morning Note: RBNZ Rate Cut, Oil Slide, Musk's Tariff Clash

Morning Note Oil
Frances Wang 2025 Apr 07, 16:00

Stock Market Today: Dow, S&P 500 Drop, Nasdaq Rises in Volatile Session

Indices Stocks
Tommy Yap 2025 Apr 07, 16:00

Morning Note: Trade Fears Hit Nvidia, Deepen US-China Clash; UK Seeks US Deal

Morning Note USD China
Frances Wang 2025 Apr 06, 16:00

Monthly Economic Report: Insights into Growth and Trends

Fed
Tommy Yap 2025 Apr 06, 16:00

Morning Note: Markets Tumble on Tariffs, Bitcoin Below $80K & Yen Gains

Morning Note Cryptocurrencies Forex
Tommy Yap 2025 Apr 05, 16:00

Week Ahead: Will U.S. Inflation Data Surprise the Market?

Forex Indices
Tommy Yap 2025 Apr 03, 16:00

Morning Note: Oil Prices Slide, US NFP Preview, Canada Jobs Data

Morning Note Oil Forex Commodities

정보

스프레드

0.06

스프레드(%)

1.1673 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 폐장

수요일

13:31 - 19:59

월요일

13:31-19:59

화요일

13:31-19:59

목요일

13:31-19:59

금요일

13:31-19:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

765257984

발행 주식 수

137143008

수익 날짜 (다음)

0000-00-00

배당수익률

배당락일

예상 연간 배당금

0

예상 연간 배당수익률

0

EPS

-3.83

이 상품에 대해 자세히 알아보기

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

관련 상품

자산
매도
매수
변동(%)

지금 거래하기

지금 거래하기

지금 거래하기

지금 거래하기
view_all_instruments
Trustpilot